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Background
ypertension (HTN) is a very common disorder with a substantial impact on public health because of its complications. Despite the high prevalence of essential hypertension (eHTN) and many researches, the basic causes remain unclear (1) (2) . Serum lipoprotein (a) [Lp(a)] is a complex lipoprotein particle which has homology structure with plasminogen of the fibrinolytic system (3). Little is known about the association of serum Lp(a) elevation with essential hypertension , while in vitro experiments have shown that oxidized Lp(a) is able to impair the arterial endothelium -dependent dilation, thus suggesting a possible role of Lp(a) in the genesis of eHTN (4).
Objectives
Few studies have shown elevated level of LP (a) in eHTN, however, results are controversial (4, 5) . Therefore, the aim of our study was to measure the serum concentrations of Lp (a) in a group of essential hypertensive patients with no clinical signs of organ damage.
Patients and Methods
This cross-sectional study was carried out on a group of essential hypertensive (eHT) patients who were documented by history, physical examination and laboratory tests. Factors served as exclusion criteria were cigarette smoking, anti-lipid drug taking, antihypertensive or any drug affecting lipids profiles. Also presence of diabetes mellitus, recent MI and vascular diseases, presence of acute or chronic infections were other exclusion criteria.
For all the patients, laboratory tests consisting of lipid profiles, serum creatinine were performed after 14 hours fasting. For all subjects serum Lp(a) was measured through enzyme immuno assay (ELISA) with Immuno-Biological Laboratories (IBL) kit of Hamburg. Normal values for Lp(a) in this study were the ones up to 39 mg/dL. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine, age and body weight. For stratification of hypertensive patients according to the report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure we stratified hypertensive patients from stage one to three (5) . For statistical analysis descriptive data are expressed as Mean± SD and frequency distribution. For correlations Spearman's rho test was used. All statistical analyses were performed using the SPSS (version 11.00) software and statistical significance was inferred at a p value< 0.05.
Results
The total subjects were 95(F =61, M =34) eHT patients. The mean ± SD of ages of hypertensive group was 57±12 years. In eHT patients, eGFR was 87±17.8 cc/min. Duration of HTN in patients were 5.5±4.5 years. In eHT patients, serum Lp(a) was 51±20mg/dL. There was no significant association between Lp(a) and stages of hypertension (p>0.05). In eHT patients an inverse correlation between seum Lp(a) and craetinin clearance was seen (r=-0.175 p<0.05). There was a significant positive correlation between serum Lp(a) and age in eHT patients (r=0.191 p<0.05) or duration of HTN (known as duration of hypertension period) (r=0.362 p<0.05).
Discussion
In this study we found, no significant association between Lp(a) and stages of hypertension. In patients, an inverse correlation between seum Lp(a) with craetinin clearance was seen. Also, there was not any significant positive correlation between serum Lp(a) and ages of hypertensive patients or duration of HTN (known as duration of hypertension period). To measure the serum concentrations of Lp(a) in a group of essential hypertensive patients not receiving pharmacological treatment and with no clinical signs of associated pathologies or organ damage, Catalano et al. conducted a study on123 Caucasian eHT patients (47 men and 76 women) (6) . They found that the hypertensive patients had higher plasma concentrations of Lp(a), total cholesterol, TG and very low density lipoprotein than controls with no differences in the plasma concentrations of Lp(a) between the two sexes (6). To evaluate Lp (a) in HTN, Bhavani et al. studied a group of eHT patients, who were not receiving pharmacological treatment and with no clinical signs of associated illness or organ damage. The study contained 37 eHT patients (27 men and 10 women) and compared with 50 controls (32 men and 18 women). It was observed that the hypertensive patients had higher plasma concentrations of Lp (a), and Lp (a) values which were correlated significantly with systolic blood pressure (SBP) diastolic blood pressure (DBP). They showed that elevated plasma Lp (a) levels were associated with hypertension (7). They concluded that higher plasma concentrations of Lp (a), albeit with in the normal range, could be an independent risk factor for atherosclerosis, and could contribute towards increasing the risk for cardiovascular diseases in persons with essential hypertension (7). To investigate whether or not Lp(a) levels is a predictor of coronary heart disease (CHD) in patients with essential hypertension, Gazzaruso et al. conducted a study in 249 patients with eHTN and in 142 non-hypertensive patients with CHD as well as in 264 healthy controls (8) . The study showed that, Lp(a) levels did not differ significantly between hypertensive and non-hypertensive patients with CHD. However, stepwise regression analysis in- 
Conclusions
Our data suggest that Lp(a), as a cofactor in essential hypertension, may be involved in a mechanism that remains to be elucidated.
